Evidence map›Paper›PMID 31590236›Full record

ArticleBiomolecules2019

Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP.

Mia San Miguel, Kristy L Martin, Jonathan Stone, Daniel M Johnstone

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Targeting Mitochondrial Complex I Deficiency in MPPBiological procedures online · 2024
    Article
  9. Article
  10. Photobiomodulation for Neurodegenerative Diseases: A Scoping Review.International journal of molecular sciences · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Photobiomodulation for Hypertension and Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mia San MiguelDiscipline of Physiology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia.
Kristy L MartinDiscipline of Physiology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia.
Jonathan StoneDiscipline of Physiology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia.
Daniel M JohnstoneDiscipline of Physiology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia. daniel.johnstone@sydney.edu.au.
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is commonly used to model Parkinson's disease (PD) as it specifically damages the nigrostriatal dopaminergic pathway. Recent studies in mice have, however, provided evidence that MPTP also compromises the integrity of the brain's vasculature. Photobiomodulation (PBM), the irradiation of tissue with low-intensity red light, mitigates MPTP-induced loss of dopaminergic neurons in the midbrain, but whether PBM also mitigates MPTP-induced damage to the cerebrovasculature has not been investigated. This study aimed to characterize the time course of cerebrovascular disruption following MPTP exposure and to determine whether PBM can mitigate this disruption. Young adult male C57BL/6 mice were injected with 80 mg/kg MPTP or isotonic saline and perfused with fluorescein isothiocyanate FITC-labelled albumin at various time points post-injection. By 7 days post-injection, there was substantial and significant leakage of FITC-labelled albumin into both the substantia nigra pars compacta (SNc;

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsBrainCerebrovascular CirculationDisease Models, AnimalFluorescein-5-isothiocyanateLow-Level Light TherapyMaleMiceMice, Inbred C57BLParkinson DiseaseRandom AllocationSerum Albumin1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineFITC-albuminFluorescein-5-isothiocyanateSerum AlbumincerebrovasculaturemouseMPTPParkinson’s diseasephotobiomodulation

Identifiers

PMID31590236
PMCPMC6843129
OpenAlexW2978355444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.